uniQure N.V. Insider Trading

QURE

Last 12 months

Insiders sold $20.9M and bought nothing on the open market.

89% of the selling was scheduled in advance under 10b5-1 plans. Chief Customer & Strat Officer Kylie O'Keefe sold 431K on Jun 11, 13% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$20.9M

0 buys · 33 sales

Under a 10b5-1 plan

89%

of the value sold

Insiders who bought / sold

0 / 12

executives and directors

Last open-market buy

None

in the last two years

Get an email when QURE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 2	Matthew C Kapusta CEO, Managing Director	Sold10b5-1 plan 3 parts	21,082	$45.16 average	952K	3.9%	Form 4
Jun 30	Walid Abi-Saab Chief Medical Officer	Sold10b5-1 plan 2 parts	30,000	$46.42 average	$1.39M	17%	Form 4
Jun 30	Jack Kaye Director	Sold10b5-1 plan 2 parts	21,167	$46.44 average	983K	45%	Form 4
Jun 26	Walid Abi-Saab Chief Medical Officer	SoldNo plan	1,434	$46.86	67K	0.8%	Form 4
Jun 24 – 25	Matthew C Kapusta CEO, Managing Director	Sold10b5-1 plan 2 parts	35,412	$50.02 average	$1.77M	6.4%	Form 4
Jun 17 – 18	Matthew C Kapusta CEO, Managing Director	Sold10b5-1 plan 8 parts	206,100	$45.47 average	$9.37M	28%	Form 4
Jun 17	Madhavan Balachandran Director	Sold10b5-1 plan 3 parts	11,685	$45.06 average	526K	21%	Form 4
Jun 17	Jack Kaye Director	Sold10b5-1 plan	5,295	$42.57	225K	17%	Form 4
Jun 15	Madhavan Balachandran Director	Sold10b5-1 plan	10,000	$27.85	279K	19%	Form 4
Jun 15	Jeannette Potts Chief Legal Officer	SoldNo plan	5,237	$27.67	145K	3.8%	Form 4
Jun 11	David D. Meek Director	SoldNo plan	1,993	$27.06	54K	4.8%	Form 4
Jun 10 – 11	Robert Gut Director	Sold10b5-1 plan 4 parts	10,278	$26.32 average	270K	24%	Form 4
Jun 11	Kylie O'Keefe Chief Customer & Strat Officer	SoldNo plan	15,936	$27.06	431K	13%	Form 4
Jun 11	Jeremy P. Springhorn Director	SoldNo plan	1,993	$27.06	54K	4.4%	Form 4
Jun 11	Leonard E Post Director	SoldNo plan	1,993	$27.06	54K	5.3%	Form 4
Jun 11	Jack Kaye Director	SoldNo plan	1,993	$27.06	54K	7.1%	Form 4
Jun 11	Rachelle Suzanne Jacques Director	SoldNo plan	1,993	$27.06	54K	5.6%	Form 4
Jun 11	Madhavan Balachandran Director	SoldNo plan	1,993	$27.06	54K	4.4%	Form 4
Jun 3	Jack Kaye Director	Sold10b5-1 plan	2,645	$30.01	79K	11%	Form 4
May 8	Walid Abi-Saab Chief Medical Officer	Sold10b5-1 plan 2 parts	45,000	$25.06 average	$1.13M	21%	Form 4
Mar 4	Matthew C Kapusta CEO, Managing Director	SoldNo plan	14,581	$9.06	132K	2.2%	Form 4
Mar 4	Walid Abi-Saab Chief Medical Officer	SoldNo plan	808	$9.06	7K	0.4%	Form 4
Mar 4	Jeannette Potts Chief Legal Officer	SoldNo plan	3,412	$9.06	31K	2.4%	Form 4
Mar 4	Christian Klemt Chief Financial Officer	SoldNo plan	12,000	$9.06	109K	5.0%	Form 4
Mar 2	Matthew C Kapusta CEO, Managing Director	SoldNo plan	34,437	$9.95	343K	5.4%	Form 4
Mar 2	Christian Klemt Chief Financial Officer	SoldNo plan	12,532	$9.95	125K	5.9%	Form 4
Mar 2	Jeannette Potts Chief Legal Officer	SoldNo plan	8,578	$9.95	85K	7.5%	Form 4
Mar 2	Walid Abi-Saab Chief Medical Officer	SoldNo plan	1,660	$9.95	17K	1.1%	Form 4
Feb 25	Matthew C Kapusta CEO, Managing Director	SoldNo plan	12,378	$23.86	295K	1.9%	Form 4
Feb 25	Christian Klemt Chief Financial Officer	SoldNo plan	6,217	$23.86	148K	2.9%	Form 4
Jan 12	Robert Gut Director	Sold10b5-1 plan 3 parts	25,613	$24.62 average	630K	44%	Form 4
Jan 9	Jack Kaye Director	Sold10b5-1 plan	6,390	$27.28	174K	24%	Form 4
Nov 6, 2025	Robert Gut Director	Sold10b5-1 plan 2 parts	31,434	$27.26 average	857K	44%	Form 4
Nov 4, 2025	Jack Kaye Director	Sold10b5-1 plan 3 parts	38,810	$30.34 average	$1.18M	66%	Form 4
Sep 24, 2025 – Sep 26, 2025	Christian Klemt Chief Financial Officer	Sold10b5-1 plan 2 parts	18,000	$52.51 average	945K	7.6%	Form 4
Sep 24, 2025	Matthew C Kapusta CEO, Managing Director	Sold10b5-1 plan 5 parts	226,316	$41.46 average	$9.38M	26%	Form 4
Jun 27, 2025	Walid Abi-Saab Chief Medical Officer	SoldNo plan	1,466	$13.92	20K	1.0%	Form 4
Jun 20, 2025	Jeremy P. Springhorn Director	SoldNo plan	2,112	$14.45	31K	5.3%	Form 4
Jun 20, 2025	Leonard E Post Director	SoldNo plan	2,112	$14.45	31K	6.6%	Form 4
Jun 20, 2025	Jack Kaye Director	SoldNo plan	2,112	$14.45	31K	9.4%	Form 4

Jul 210b5-1 plan
Matthew C Kapusta
CEO, Managing Director · sold 21,082 at avg $45.16
952K
3.9% of stake
Jun 3010b5-1 plan
Walid Abi-Saab
Chief Medical Officer · sold 30,000 at avg $46.42
$1.39M
17% of stake
Jun 3010b5-1 plan
Jack Kaye
Director · sold 21,167 at avg $46.44
983K
45% of stake
Jun 26No plan
Walid Abi-Saab
Chief Medical Officer · sold 1,434 at $46.86
67K
0.8% of stake
Jun 24 – 2510b5-1 plan
Matthew C Kapusta
CEO, Managing Director · sold 35,412 at avg $50.02
$1.77M
6.4% of stake
Jun 17 – 1810b5-1 plan
Matthew C Kapusta
CEO, Managing Director · sold 206,100 at avg $45.47
$9.37M
28% of stake
Jun 1710b5-1 plan
Madhavan Balachandran
Director · sold 11,685 at avg $45.06
526K
21% of stake
Jun 1710b5-1 plan
Jack Kaye
Director · sold 5,295 at $42.57
225K
17% of stake
Jun 1510b5-1 plan
Madhavan Balachandran
Director · sold 10,000 at $27.85
279K
19% of stake
Jun 15No plan
Jeannette Potts
Chief Legal Officer · sold 5,237 at $27.67
145K
3.8% of stake
Jun 11No plan
David D. Meek
Director · sold 1,993 at $27.06
54K
4.8% of stake
Jun 10 – 1110b5-1 plan
Robert Gut
Director · sold 10,278 at avg $26.32
270K
24% of stake
Jun 11No plan
Kylie O'Keefe
Chief Customer & Strat Officer · sold 15,936 at $27.06
431K
13% of stake
Jun 11No plan
Jeremy P. Springhorn
Director · sold 1,993 at $27.06
54K
4.4% of stake
Jun 11No plan
Leonard E Post
Director · sold 1,993 at $27.06
54K
5.3% of stake
Jun 11No plan
Jack Kaye
Director · sold 1,993 at $27.06
54K
7.1% of stake
Jun 11No plan
Rachelle Suzanne Jacques
Director · sold 1,993 at $27.06
54K
5.6% of stake
Jun 11No plan
Madhavan Balachandran
Director · sold 1,993 at $27.06
54K
4.4% of stake
Jun 310b5-1 plan
Jack Kaye
Director · sold 2,645 at $30.01
79K
11% of stake
May 810b5-1 plan
Walid Abi-Saab
Chief Medical Officer · sold 45,000 at avg $25.06
$1.13M
21% of stake
Mar 4No plan
Matthew C Kapusta
CEO, Managing Director · sold 14,581 at $9.06
132K
2.2% of stake
Mar 4No plan
Walid Abi-Saab
Chief Medical Officer · sold 808 at $9.06
7K
0.4% of stake
Mar 4No plan
Jeannette Potts
Chief Legal Officer · sold 3,412 at $9.06
31K
2.4% of stake
Mar 4No plan
Christian Klemt
Chief Financial Officer · sold 12,000 at $9.06
109K
5.0% of stake
Mar 2No plan
Matthew C Kapusta
CEO, Managing Director · sold 34,437 at $9.95
343K
5.4% of stake
Mar 2No plan
Christian Klemt
Chief Financial Officer · sold 12,532 at $9.95
125K
5.9% of stake
Mar 2No plan
Jeannette Potts
Chief Legal Officer · sold 8,578 at $9.95
85K
7.5% of stake
Mar 2No plan
Walid Abi-Saab
Chief Medical Officer · sold 1,660 at $9.95
17K
1.1% of stake
Feb 25No plan
Matthew C Kapusta
CEO, Managing Director · sold 12,378 at $23.86
295K
1.9% of stake
Feb 25No plan
Christian Klemt
Chief Financial Officer · sold 6,217 at $23.86
148K
2.9% of stake
Jan 1210b5-1 plan
Robert Gut
Director · sold 25,613 at avg $24.62
630K
44% of stake
Jan 910b5-1 plan
Jack Kaye
Director · sold 6,390 at $27.28
174K
24% of stake
Nov 6, 202510b5-1 plan
Robert Gut
Director · sold 31,434 at avg $27.26
857K
44% of stake
Nov 4, 202510b5-1 plan
Jack Kaye
Director · sold 38,810 at avg $30.34
$1.18M
66% of stake
Sep 24, 2025 – Sep 26, 202510b5-1 plan
Christian Klemt
Chief Financial Officer · sold 18,000 at avg $52.51
945K
7.6% of stake
Sep 24, 202510b5-1 plan
Matthew C Kapusta
CEO, Managing Director · sold 226,316 at avg $41.46
$9.38M
26% of stake
Jun 27, 2025No plan
Walid Abi-Saab
Chief Medical Officer · sold 1,466 at $13.92
20K
1.0% of stake
Jun 20, 2025No plan
Jeremy P. Springhorn
Director · sold 2,112 at $14.45
31K
5.3% of stake
Jun 20, 2025No plan
Leonard E Post
Director · sold 2,112 at $14.45
31K
6.6% of stake
Jun 20, 2025No plan
Jack Kaye
Director · sold 2,112 at $14.45
31K
9.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch QURE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with QURE

CompareIntrinsic value

EVFMEvofem Biosciences Inc.

$0.01+0.00%15

CTMXCytomX Therapeutics Inc.

$2.35+7.80%10

CELUCelularity Inc.

$0.81-1.00%0

ANABAnaptysBio Inc.

$47.51-0.46%20

SCYXScynexis, Inc.

$3.84-2.54%40

SLGLSol-Gel Technologies Ltd.

$66.00+3.43%65

KPRXKiora Pharmaceuticals Inc.

$1.66-4.05%10

EMMAEmmaus Life Sciences, Inc.

$0.03-17.50%21

Held by ETFs

QURE is in 22 US ETFs. The largest of them, with QURE's weight in each:

Spot a number that looks wrong? Check it in QURE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing QURE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.